Unlock instant, AI-driven research and patent intelligence for your innovation.

Methods and compositions targeting viral and cellular ITAM motifs, and use of same in identifying compounds with therapeutic activity

Inactive Publication Date: 2007-05-17
THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
View PDF5 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008] In another embodiment, the present invention provides a method of reducing an incidence of a carcinoma in a subject, comprising administering to the subject a compound that inhibits an interaction of a first protein and an ITAM of a second protein, thereby reducing an incidence of a carcinoma in a subject.
[0011] In another embodiment, the present invention provides a method of reducing an incidence of a sarcoma in a subject, comprising administering to the subject a compound that inhibits an interaction of a first protein and an ITAM of a second protein, thereby reducing an incidence of a sarcoma in a subject.
[0014] In another embodiment, the present invention provides a method of reducing an incidence of an Epstein-Barr virus-induced malignancy in a subject, comprising administering to the subject a compound that inhibits an interaction of a first protein and an ITAM of a second protein, thereby reducing an incidence of an Epstein-Barr virus-induced malignancy in a subject.
[0017] In another embodiment, the present invention provides a method of reducing an incidence of a B cell proliferative disorder in a subject, comprising administering to the subject a compound that inhibits an interaction of a first protein and an ITAM of a second protein, thereby reducing an incidence of a pathological immune cell activation in a subject.
[0019] In another embodiment, the present invention provides a method of reducing an incidence of a mast cell activation disorder in a subject, comprising administering to the subject a compound that inhibits an interaction of a first protein and an ITAM of a second protein, thereby reducing an incidence of a mast cell activation disorder in a subject.

Problems solved by technology

In addition, a variety of immune cell activation diseases and disorders (e.g. B cell proliferative diseases and disorders and mast cell activation diseases and disorders) cause significant morbidity and mortality in the human population.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions targeting viral and cellular ITAM motifs, and use of same in identifying compounds with therapeutic activity
  • Methods and compositions targeting viral and cellular ITAM motifs, and use of same in identifying compounds with therapeutic activity
  • Methods and compositions targeting viral and cellular ITAM motifs, and use of same in identifying compounds with therapeutic activity

Examples

Experimental program
Comparison scheme
Effect test

example 1

Expression of ITAM-Containing MMTV ENV Leads to Depolarization of Mammary Epithelial Acinar Structures

Materials and Experimental Methods (Examples 1-4)

Cell Lines

[0121] NMuMG and MCF-10F cell lines were obtained from the American Type Culture Collection. MMTV-transfected clones of the NMuMG cell line were generated by transfecting NMuMG cells with MMTV. Clones expressing high levels of MMTV virions were selected. All NMuMG cell lines were maintained in DMEM containing 10% heat-inactivated FBS, 2 mM L-glutamine, 100 U / ml penicillin-streptomycin, and 10 μg / ml insulin at 37° C. and 5% CO2.

[0122] Cell transfections were accomplished using the GenePorter® system (Gene Therapy Systems). The Q61 plasmid was used for complete envelope expression. Y>F mutations in the MMTV SU tyrosine residues were introduced using the Quickchange® XL kit (Stratagene). Stable pools were generated and maintained by sorting for SUhi expressing cells every 5-10 passages.

Flow Cytometry

[0123] Cells grown i...

example 2

SRC and SYK Tyrosine Kinases Contribute to MMTV ENV-Induced Acinar Depolarization

[0134] In lymphocytes, ITAM signaling is dependent, under the conditions utilized herein, on activity of two tyrosine kinase families, the Src family kinases and the smaller Syk / Zap-70 family kinases. To directly show the role of the SU ITAM domain in signaling, direct interaction between the MMTV SU and Syk kinase was measured in the presence of tyrosine phosphatase inhibitors. Up to 34% SU protein co-immunoprecipitated with Syk (three independent experiments; FIG. 2 A). To confirm this finding, pharmacologic inhibitors of either Src (PP2) or Syk / ZAP70 (piceatannol) were shown to be sufficient to block morphological changes associated with Env transformation (FIG. 2B; quantification for one representative experiment depicted in FIG. 2C).

[0135] These findings provide further evidence that the ITAM was responsible for the observed cell transformation.

example 3

MMTV ENV-Expressing Cells Exhibit a Transformed Mammary Epithelial Phenotype

[0136] NMuMG cells stably expressing infectious MMTV virus were also evaluated. These cells (MMTV+ cells) exhibited morphological features resembling mesenchymal cells in three-dimensional cultures and a greater degree of depolarization in comparison with NMuMG.Q4 cells (FIG. 3A). A higher level of surface MMTV SU expression (FIG. 1C) or positional effects due to virus integration and long-term culture likely accounts for the differences between the MMTV+ cells and the NMuMG.Q4 cells.

[0137] NMuMG.Q4 and MMTV+ cells both exhibited down-regulation of Keratin-18 and E-cadherin expression, indicators of epithelial-mesenchymal transition, (FIG. 3 B, left panel), while expression of these markers in NMuMG.F6 cells closely resembled wild-type and mock-transfected cells. Down-regulation of E-cadherin surface expression could also be detected in Env-expressing cells maintained in two-dimensional cultures (FIG. 3 B,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention provides methods of treating, reducing the incidence of, and inhibiting metastasis formation of carcinomas, sarcomas, Epstein-Barr virus-induced malignancies, B cell proliferative disorders, and mast cell activation disorders, comprising administering to a subject a compound that inhibits an interaction of a first protein and an immunoreceptor tyrosine-based activation motif (ITAM) of a second protein, and screening methods for identifying ITAM-inhibitory compounds and peptides. This invention also provides peptides that inhibit signaling by ITAMs.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority of U.S. Provisional Application Ser. No. 60 / 643,906, filed Jan. 14, 2005, and U.S. Provisional Application Ser. No. 60 / 649,900, filed Feb. 4, 2005. These applications are hereby incorporated in their entirety by reference herein.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT [0002] The invention described herein was supported in whole or in part by grants from The National Institutes of Health (Grant Numbers P01-CA093615, R01-A143620, R01-CA087609, R01-CA073746, RO1-A132592, and CA09140) and the Department of Defense (Grant Numbers DMAD17-00-1-0249 and W81WH-04-1-0435). The government has certain rights in the invention.FIELD OF INVENTION [0003] This invention provides methods of treating, reducing the incidence of, and inhibiting metastasis formation of carcinomas, sarcomas, Epstein-Barr virus-induced malignancies, B cell proliferative disorders, and mast cell activation disorders, comp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/00A61K38/17
CPCA61K38/1709A61P35/04
Inventor MONROE, JOHN G.KATZ, ELADMURALI, RAMACHANDRAN
Owner THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More